CHRS in the 13F filings
Coherus Oncology Inc · CUSIP 19249H103
- Quarter end
- 30 Jun 2023
- the date the book describes
- Filed
- 15 Aug 2023
- latest of these filings; the earliest 28 Jul 2023
- Managers listing it
- 1
- at least, of 95 tracked, among listed positions
- Comparable managers
- 93
- filed both Q1 2023 and Q2 2023; 0 listed it in both
- Shares listed
- 500,000
- combined, among listed positions
- Reported value
- $2.1m
- combined, at the quarter end
Managers listing CHRS in Q2 2023
Share of 13F value is the position’s reported value over everything the manager reported that quarter. The share change is against Q1 2023, and only where both filings list the position. A rise in value with no rise in shares is the price, not buying.
1 of 1 holder
| Action | Filing | |||||
|---|---|---|---|---|---|---|
| Woodline Partners LP | 500,000 | $2.1m | under 0.1% | New | new | 14 Aug 2023 (the filing on sec.gov) |
Largest increases and reductions, by shares
Q1 2023 to Q2 2023, among managers that listed it in both quarters or opened it.
Increases
- Woodline Partners LPnew position · 500,000 shares now+500,000
Reductions
No reduction among listed positions.
New positions and exits
At least these many: a manager is shown exiting only where its own filing shows the position gone.
New (1)
- Woodline Partners LP$2.1m
Exited (2)
- Caxton Associates LLPwas $767k
- Baillie Gifford & Cowas $11k
Ownership over time
Every quarter on file. A quarter-end value moves with the price as well as with the shares held; buyers and sellers count comparable managers, by shares.
2 in Q3 2022 to 1 in Q2 2024
Tracked managers listing it, at least.
the quarter shown share split complete books; unmarked quarters rest on listed positionsClick a quarter to open it.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q2 2015 | 1 | $3.7m | n.a. | n.a. |
| Q3 2015 | 2 | $5.5m | n.a. | n.a. |
| Q4 2015 | 1 | $2.9m | n.a. | n.a. |
| Q3 2016 | 1 | $27m | n.a. | n.a. |
| Q4 2016 | 1 | $17m | n.a. | n.a. |
| Q2 2018 | 1 | $12m | n.a. | n.a. |
| Q3 2018 | 2 | $142m | n.a. | n.a. |
| Q1 2019 | 3 | $17m | n.a. | n.a. |
| Q2 2019 | 3 | $155m | n.a. | n.a. |
| Q3 2019 | 1 | $133m | n.a. | n.a. |
| Q4 2019 | 5 | $13m | n.a. | n.a. |
| Q1 2020 | 7 | $65m | n.a. | n.a. |
| Q2 2020 | 2 | $75m | n.a. | n.a. |
| Q3 2020 | 3 | $86m | n.a. | n.a. |
| Q4 2020 | 4 | $85m | n.a. | n.a. |
| Q1 2021 | 3 | $3.3m | n.a. | n.a. |
| Q2 2021 | 3 | $3.1m | n.a. | n.a. |
| Q3 2021 | 1 | $26k | n.a. | n.a. |
| Q4 2021 | 4 | $95m | n.a. | n.a. |
| Q1 2022 | 3 | $78m | n.a. | n.a. |
| Q2 2022 | 1 | $10k | n.a. | n.a. |
| Q3 2022 | 2 | $59m | n.a. | n.a. |
| Q4 2022 | 1 | $13k | n.a. | n.a. |
| Q1 2023 | 2 | $778k | n.a. | n.a. |
| Q2 2023 | 1 | $2.1m | n.a. | n.a. |
| Q3 2023 | 3 | $2.2m | n.a. | n.a. |
| Q4 2023 | 2 | $3.6m | 1 | 1 |
| Q1 2024 | 2 | $3.0m | 2 | 0 |
| Q2 2024 | 1 | $558k | 0 | 1 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
CHRS and GILD →CHRS and AMGN →CHRS and ARGX →Choose a stock to compare with CHRS →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own CHRS, latest filings →Back to the 13F Explorer →